Daily Newsletter

29 November 2023

Daily Newsletter

29 November 2023

Clario introduces AI-powered tool for cardiac safety evaluations in trials

The tool acts as an insurance policy for prospective clinical trials.

RanjithKumar Dharma November 29 2023

Clario has introduced the ECG Quality Score tool, powered by artificial intelligence (AI), for improving cardiac safety evaluations in clinical trials.

The new tool includes the Early Precision QT Quality Summary Report and the Early Precision QT Quality Detailed Report. Both reports offer granular information regarding the quality of ECG data collected.

It utilises an AI and machine learning (ML) method trained on more than 80,000 Phase I healthy volunteer ECGs to provide in-depth insights into whether the continuously collected ECG data meets the required quality for subsequent Early Precision QT (EPQT).

By improving data quality assurance and reducing risks, the tool provides valuable insights and reassurance to sponsors.

The tool provides a proactive approach to evaluating quality, assisting sponsors in real-time quality monitoring.

It can address issues through solutions such as site training or additional recruitment while the study is ongoing.

Furthermore, the tool serves as an insurance policy for prospective clinical trials with planned EPQT evaluation.

It is also specifically important for studies where ECG data is stored for potential evaluation in the future.

Clario Cardiac Safety executive vice-president Ellen Street said: “Clario’s ECG Quality Score tool embodies our unwavering commitment to advancing trials and technologies through the use of AI/ML.

“We aim to provide sponsors with better insights into cardiac safety earlier in the drug development process and equip them with the tools needed to make informed decisions and collect higher quality data.”

At first, the company will offer the tool to Clario Certified Sites as part of its commitment to provide the latest technology to its closest partners.

Last month, Clario announced that researchers from the University of Oxford leveraged its Precision Motion Opal wearable sensor technology for a study to better understand motor symptom progression in individuals with Parkinson’s disease.

The aging population is a captive market for medical devices

The rising number of older individuals globally is accompanied by increasing health concerns, presenting unique demand for the medical device industry. With rising pressure on governments, payers, and manufacturers to reduce healthcare costs, innovative medical technologies have tremendous potential to improve elder care. Advancements in medical device technology have resulted in a significant increase in the number of conditions that can be managed in a home care setting. To capitalize on this strong demand and growth, manufacturers are increasingly producing consumer-targeted equipment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close